The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Intracranial efficacy of sotorasib versus docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer (NSCLC): Practice-informing data from a global, phase 3, randomized, controlled trial (RCT).
 
Anne-Marie C. Dingemans
Consulting or Advisory Role - AstraZeneca (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Daiichi Sankyo/Lilly (Inst); Janssen Oncology (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Speakers' Bureau - AstraZeneca (Inst); Janssen (Inst); Lilly (Inst); Pfizer (Inst); Pfizer (Inst)
Research Funding - Amgen (Inst)
 
Konstantinos Syrigos
No Relationships to Disclose
 
Lorenzo Livi
No Relationships to Disclose
 
Astrid Paulus
Consulting or Advisory Role - Roche
Research Funding - Amgen (Inst); AstraZeneca (Inst)
Travel, Accommodations, Expenses - Takeda
 
Sang-We Kim
No Relationships to Disclose
 
Yuanbin Chen
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Mirati Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol-Myers Squibb; Guardant Health; Jazz Pharmaceuticals; Pfizer; Takeda
Other Relationship - Amgen - Local PI (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Helsinn Therapeutics (Inst); Ipsen (Inst); Merck (Inst)
 
Enriqueta Felip
Consulting or Advisory Role - Amgen; AstraZeneca; Bayer; BerGenBio; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; F. Hoffmann LaRoche; GlaxoSmithKline; Janssen; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Peptomyc; Pfizer; Sanofi; Takeda; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; F. Hoffmann LaRoche; Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; PeerVoice; Pfizer; Sanofi; Takeda; Touch Oncology
Research Funding - Merck (Inst); Merck KGaA (Inst)
Other Relationship - GRIFOLS
 
Frank Griesinger
Honoraria - Abbvie; Amgen; ARIAD; AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Lilly O.; MSD; Novartis; Pfizer; Roche; Sanofi; Siemens; Takeda; Tesaro; Tesaro/GSK
Consulting or Advisory Role - Abbvie; Amgen; ARIAD; AstraZeneca; BeiGene; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Daiichi Sankyo; Lilly O.; MSD; Novartis; Pfizer; Roche; Sanofi; Siemens; Takeda; Tesaro; Tesaro/GSK
Speakers' Bureau - Abbvie; Amgen; ARIAD; AstraZeneca; BeiGene; Boehringer Ingelheim; Celgene; Daiichi Sankyo; Lilly O.; MSD; Novartis; Pfizer; Roche; Sanofi; Siemens; Takeda; Tesaro; Tesaro/GSK
Research Funding - Abbvie (Inst); Amgen (Inst); ARIAD (Inst); AstraZeneca (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo (Inst); Lilly O. (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Sanofi (Inst); Siemens (Inst); Takeda (Inst); Tesaro/GSK (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly O.; MSD; Novartis; Pfizer; Roche; Siemens; Takeda
 
Kadoaki Ohashi
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Kyowa Kirin; Lilly O.; MSD; Nippon Kayaku; Novartis
Research Funding - AstraZeneca/MedImmune; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo Pharmaceutical; Lilly O.
 
Gerard Zalcman
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Da Volterra; Inventiva Pharma; Lilly; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Bristol-Myers Squibb (Inst); Da Volterra (Inst); Inventiva Pharma (Inst); MSD Oncology (Inst); Pfizer (Inst); Roche (Inst)
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Pfizer (Inst); Roche (Inst); ROCHE (Inst); ROCHE (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - Abbvie; AstraZeneca; AstraZeneca; AstraZeneca; Bristol-Myers Squibb; Lilly; Pfizer; Pfizer; Roche
 
Brett Gordon Maxwell Hughes
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Eisai; MSD Oncology; Pfizer; Roche; Sanofi/Aventis; Takeda
Research Funding - Amgen (Inst)
 
Jens Benn Sorensen
No Relationships to Disclose
 
Normand Blais
Consulting or Advisory Role - Amgen
 
Carlos G. M. Ferreira
Employment - Oncoclinicas & Co
Stock and Other Ownership Interests - Oncoclinicas & Co
Consulting or Advisory Role - AstraZeneca
Speakers' Bureau - BeiGene
 
Colin R Lindsay
Honoraria - Amgen
Consulting or Advisory Role - Amgen; cbpartners
Research Funding - Revolution Medicines (Inst)
(OPTIONAL) Uncompensated Relationships - Amgen; Amgen
 
Rafal Dziadziuszko
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD Oncology; Novartis; Roche/Genentech; Takeda
Consulting or Advisory Role - Karyopharm Therapeutics
Travel, Accommodations, Expenses - AstraZeneca; Pfizer; Roche
 
Patrick J. Ward
Employment - Bon Secours Mercy Health (I)
Consulting or Advisory Role - Amgen
 
Cynthia Chinedu Obiozor
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Yang Wang
Employment - Amgen
Stock and Other Ownership Interests - Amgen
 
Solange Peters
Honoraria - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Ecancer (Inst); Ecancer (Inst); Fishawack Facilitate (Inst); Illumina (Inst); Imedex (Inst); Incyte (Inst); medscape (Inst); Medtoday (Inst); Mirati Therapeutics (Inst); MSD (Inst); Novartis (Inst); OncologyEducation (Inst); Peerview (Inst); PER (Inst); Pfizer (Inst); Prime Oncology (Inst); Research to Practice (Inst); RMEI Medical Education (Inst); Roche (Inst); Sanofi (Inst); Takeda (Inst)
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); Bayer (Inst); Biocartis (Inst); Bioinvent (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); F-Star Biotechnology (Inst); Foundation Medicine (Inst); Genzyme (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Illumina (Inst); Incyte (Inst); ITeos Therapeutics (Inst); Janssen (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Phosplatin Therapeutics (Inst); Regeneron (Inst); Roche/Genentech (Inst); Sanofi (Inst); Seagen (Inst); Takeda (Inst); Vaccibody (Inst); Vaccibody (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Biodesix (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Illumina (Inst); Iovance Biotherapeutics (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Phosplatin Therapeutics (Inst); roche (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Incyte; MSD; Roche; Sanofi
(OPTIONAL) Uncompensated Relationships - Annals of Oncology (I); ESMO; ETOP Scientific chair; JTO Past Deputy Editor; SAMO President